Infinity Pharmaceuticals has appointed José Baselga M.D., Ph.D., and Jeff Berkowitz as independent members of its board of directors. Baselga, physician-in-chief at Memorial Sloan-Kettering Cancer Center, is an accomplished clinician and a thought leader in the PI3K field. Berkowitz, as the president of Walgreens Boots Alliance Development in Europe, has experience in pharmaceuticals, pharmacy, distribution and market access, pricing and reimbursement.

“Baselga’s knowledge in oncology drug discovery and development is a great asset, which will be important aswe move our pipeline forward through the clinical and regulatory process. Berkowitz brings a wealth of experience with the changing world of global reimbursement, together with U.S. and European regulatory and commercial dynamics,” said Adelene Q. Perkins, chair and chief executive officer of Infinity.

Infinity also announced that Thomas Lynch, M.D., and Martin Babler have retired from the board. Lynch and Babler were important contributors as Infinity built its initial clinical organization and developed early market insights that informed the company’s clinical development strategies.

Baselga has been physician-in-chief at Memorial Sloan-Kettering Cancer Center since January 2013. He formerly was chief and Bruce A. Chabner chair of the Division of Hematology/Oncology at Massachusetts General Hospital (MGH), associate director of the MGH Cancer Center and professor of Medicine at Harvard Medical School. Baselga also was associate director of Clinical Services at Dana-Farber/Harvard Cancer Center. From 1996 to 2010, Baselga was chairman of the Medical Oncology Service and director of the Division of Medical Oncology, Hematology and Radiation Oncology at the Vall d'Hebron Institute of Oncology in Barcelona, Spain. Baselga previously was the president of the European Society of Medical Oncology and worked on the board of directors of the American Society of Clinical Oncology (ASCO). He currently is a member of the board of directors of the American Association for Cancer Research (AACR).

Berkowitz is president of Walgreens Boots Alliance Development and is senior vice president of Pharmaceutical Development and Market Access of Walgreen Co. As part of Walgreens’ strategic partnership with Alliance Boots, Berkowitz is responsible for the creation and development of a new joint venture company based in Europe. Berkowitz and his team lead all of Walgreens’ relations with branded and generic pharmaceutical manufacturers and related development programs worldwide, and also oversee Walgreens North American-based purchasing and branded pharmaceutical relationships. As the senior-most Walgreens executive residing outside of the U.S., Berkowitz leads the global health and wellbeing efforts on the ground overseas. Previously, Berkowitz was senior vice president of global market access for Merck. In that role, he was accountable for all activity related to access, pricing, payer marketing, health outcomes and health technology assessments worldwide and a member of the Global Human Health and Emerging Markets leadership teams. From 2002 to 2009, Berkowitz held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009.